2304462
Project Grant
Overview
Grant Description
Sbir Phase I: Development of a Novel, Sprayable, Large Volume Hydrogel Delivery System Platform -The Broader Impact/Commercial Potential of This Small Business Innovation Research (SBIR) Phase I Project Is a Simplified System for Applying Compound In Situ to Form Biomaterials During Surgical Procedures. Controlled Biomaterial Applications Pose Significant Potential Surgical Advantages Including for Anti-Adhesion, Tissue Sealant, and Drug Delivery Purposes.
The Proposed Platform Will Enable Procedural Consistency to Provide New and Improved Ways to Manage Bleeding and Reduce Scar Tissue Formation During Surgical Procedures. This Product Aims to Gain a Share of the $1.5 Billion Adhesion Prevention Market and $1.2 Billion Hemostat Market, and Enable Eventual Site-Specific Delivery Cells and Drugs, Depending on the Biomaterial Delivered.
This Small Business Innovation Research (SBIR) Phase I Project Will Develop a Ready-to-Use, Large Volume Delivery System for In Situ Forming Biomaterials. The Scope of Activities Includes Transferring a Novel, Proprietary, In Situ Biomaterial with Applicability as a Tissue Sealant, Scar Tissue Reductant, and Drug/Cell Delivery Vehicle, into a Novel Single Use Applicator.
The Prepackaged Delivery System Will Formulate the Suspended Biomaterial with the Resuspension Solution Using an Internal Mechanical Mechanism Which Delivers the Biomaterial in a Controlled Aerosolized Manner Suitable for Clinical Use.
This Phase 1 Project Aims to Complete and Validate Prototypes with Lyophilized Biomaterials Within Good Manufacturing Practices, Engineer the Design of the Syringe Barrel and Delivery Tips/Nozzles, and Complete Laboratory Validation in a Manner Suitable for First in Human Use.
This Award Reflects Nsf's Statutory Mission and Has Been Deemed Worthy of Support Through Evaluation Using the Foundation's Intellectual Merit and Broader Impacts Review Criteria.- Subawards Are Not Planned for This Award.
The Proposed Platform Will Enable Procedural Consistency to Provide New and Improved Ways to Manage Bleeding and Reduce Scar Tissue Formation During Surgical Procedures. This Product Aims to Gain a Share of the $1.5 Billion Adhesion Prevention Market and $1.2 Billion Hemostat Market, and Enable Eventual Site-Specific Delivery Cells and Drugs, Depending on the Biomaterial Delivered.
This Small Business Innovation Research (SBIR) Phase I Project Will Develop a Ready-to-Use, Large Volume Delivery System for In Situ Forming Biomaterials. The Scope of Activities Includes Transferring a Novel, Proprietary, In Situ Biomaterial with Applicability as a Tissue Sealant, Scar Tissue Reductant, and Drug/Cell Delivery Vehicle, into a Novel Single Use Applicator.
The Prepackaged Delivery System Will Formulate the Suspended Biomaterial with the Resuspension Solution Using an Internal Mechanical Mechanism Which Delivers the Biomaterial in a Controlled Aerosolized Manner Suitable for Clinical Use.
This Phase 1 Project Aims to Complete and Validate Prototypes with Lyophilized Biomaterials Within Good Manufacturing Practices, Engineer the Design of the Syringe Barrel and Delivery Tips/Nozzles, and Complete Laboratory Validation in a Manner Suitable for First in Human Use.
This Award Reflects Nsf's Statutory Mission and Has Been Deemed Worthy of Support Through Evaluation Using the Foundation's Intellectual Merit and Broader Impacts Review Criteria.- Subawards Are Not Planned for This Award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF22551
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Houston,
Texas
77021-2039
United States
Geographic Scope
Single Zip Code
Related Opportunity
22-551
Karios Technologies was awarded
Project Grant 2304462
worth $274,954
from National Science Foundation in August 2023 with work to be completed primarily in Houston Texas United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I:Development of a Novel, Sprayable, Large Volume Hydrogel Delivery System Platform
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a simplified system for applying compound in situ to form biomaterials during surgical procedures. Controlled biomaterial applications pose significant potential surgical advantages including for anti-adhesion, tissue sealant, and drug delivery purposes. The proposed platform will enable procedural consistency to provide new and improved ways to manage bleeding and reduce scar tissue formation during surgical procedures. This product aims to gain a share of the $1.5 billion adhesion prevention market and $1.2 billion hemostat market, and enable eventual site-specific delivery cells and drugs, depending on the biomaterial delivered._x000D__x000D_ This Small Business Innovation Research (SBIR) Phase I project will develop a ready-to-use, large volume delivery system for in situ forming biomaterials. The scope of activities includes transferring a novel, proprietary, in situ biomaterial with applicability as a tissue sealant, scar tissue reductant, and drug/cell delivery vehicle, into a novel single use applicator. The prepackaged delivery system will formulate the suspended biomaterial with the resuspension solution using an internal mechanical mechanism which delivers the biomaterial in a controlled aerosolized manner suitable for clinical use.This Phase 1 project aims to complete and validate prototypes with lyophilized biomaterials within good manufacturing practices, engineer the design of the syringe barrel and delivery tips/nozzles, and complete laboratory validation in a manner suitable for first in human use._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
MD
Solicitation Number
NSF 22-551
Status
(Complete)
Last Modified 9/5/23
Period of Performance
8/15/23
Start Date
7/31/24
End Date
Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2304462
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
GWK4KUD2L8E8
Awardee CAGE
8NWB8
Performance District
TX-18
Senators
John Cornyn
Ted Cruz
Ted Cruz
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $274,954 | 100% |
Modified: 9/5/23